The Use of ¹²⁵Iodine for Precordial Counting³

Ralph J. Gorten, M.D.^{1,2}

Durham, North Carolina

The physical characteristics and particular advantages of ¹²⁵iodine have been extolled in the literature of the past several years (1-3). With the development of more economical production methods, this isotope has been found useful in application to various diagnostic procedures (3-9). Determination of cardiac output by precordial counting of this soft gamma emitter has not been previously described. This communication reports the use of ¹²⁵iodine labeled albumin for this purpose.

METHOD

Radioiodinated (¹²⁵I) human serum albumin, which has a half-life of about 57 days and emits a 27.4 kev x-ray and a 35.4 kev gamma ray, was obtained from E. R. Squibb and Sons or Volk Radiochemical Company. Each day some of the sterile stock solution was diluted to 40 μ c/ml. It was rapidly injected into an antecubital vein in doses of 0.5 ml (20 μ c) for the first and 1.0 ml (40 μ c) for a second determination.

For precordial counting of blood flow through the heart, a Nuclear-Chicago Corporation Model DS8-21 Miniature Scintillation Detector was used. It contains a thallium activated sodium iodide wafer crystal 2 mm thick and 18 mm in diameter which is reported to be at least 98 per cent efficient for 30 kev energies (1, 3). The crystal is covered by a beryllium window 0.005 inch thick which allows low energy radiations to pass without appreciable loss. The instrument includes also a short lucite light pipe, a photomultiplier tube (Dumont K1692) and a small preamplifier. The whole detector has dimensions of 10×1 inches and weighs 175 grams.

With a patient in a comfortable supine position, the detector, supported by a ring stand, was centered over the heart (third or fourth intercostal space,

¹With the technical assistance of Judith R. Forrest, B. S.

²From the Radioisotope and Medical Services, Veterans Administration Hospital and the Department of Medicine, Duke University Medical Center, Durham, North Carolina.

³This investigation was supported in part by a grant from the North Carolina Heart Association.

RALPH J. GORTEN

1 cm to the left of the sternal border) with its long axis perpendicular to the chest wall. Time concentration curves representing cardiac (and pulmonary) transit of the ¹²⁵I albumin bolus were counted on a conventional linear ratemeter (Nuclear-Chicago 1620 CS) and a milliammeter recorder (Texas Instruments, Inc.). The procedure for exponential extrapolation and calculation of cardiac output from curve area and equilibrium level is the same as for ¹³¹I albumin and has been described in detail previously (10, 11). Total blood volume was measured in conjunction with the first cardiac output in each patient.

In 16 patients, some of whom had heart disease, results of ¹²⁵I albumin determinations were compared to those with ¹³¹I albumin (10-20 μ c per dose). The latter required conventional 2 inch detectors with lead shielding and narrow angle (20°) collimation (Nuclear-Chicago Corp. DS-5). Four determinations two with each method—were generally carried out in alternating sequence. In 10 patients, this was started with ¹²⁵I albumin; in the other 6 individuals, ¹³¹I albumin was used first. All determinations in a patient were completed within one hour. Both indicators contributed to background radioactivity levels counted with either detector in subsequent determinations in an individual. This was of no consequence, however, because the calculations are based on relative changes in precordial count rates following each dose.

The ¹²⁵I and the ¹³¹I values for cardiac output were compared in each patient to calculate the correlation coefficient and "p" value. The older, established ¹³¹I albumin method was used as the basis of comparison.

RESULTS

Enough soft energy photons from ¹²⁵I albumin in blood within the heart were detected by the small external counter to record adequate indicator dilution curves. With intravenously injected doses of 20-40 μ c, well defined curves were repeatedly observed with peak concentration levels 2,500–20,000 cpm above preinjection baselines (Fig. 1). Qualitative inspection revealed these curves to be similar in each individual to those obtained by the ¹³¹I method which included narrow angle collimation. For instance, the peaks of the two curves in Fig. 1 were formed with marked similarity, as were the downslopes and the manner in which recirculation began. While these two curves were recorded with the same shape, their overall size is different. This is, however, a function of the dose, the ratemeter sensitivity setting, and certain geometrical relationships. In Fig. 2 the curves are alike in the height reached as well as in overall shape.

Cardiac output values for the 16 patients are listed in the Table. While there was generally good agreement between the technics, in some patients there was considerable variation in the four consecutive cardiac output determinations. Despite precautions to provide comfort and rest, variation in blood flow of this magnitude may well occur within an hour in unsedated patients. The arithmetic mean of the differences between ¹²⁵I and ¹³¹I results in each individual was + 0.013 liters/min indicating the absence of any systematic difference. Also, there was good correlation of the ¹²⁵I output values against the ¹³¹I results (r = 0.734). The "p" value for this correlation coefficient was less than 0.001, strongly suggesting that the two techniques were measuring the same variable.



Fig. 1. Consecutive precordial indicator dilution curves on patient H.E. Curve on right: Ten μc ¹³¹I albumin; meter setting 50,000 cpm full scale deflection; peak concentration 38,500 cpm above baseline; cardiac output 8.0 L/min (cardiac index 3.9 L/min/M²). Curve on left: Forty μc ¹²⁵I albumin; meter setting 30,000 cpm; peak 14,500 cpm above baseline; cardiac output 7.7 L/min (cardiac index 3.7 L/min/M²).



Fig. 2. Consecutive precordial dilution curves on patient W. H. Curve on left: Forty μc^{125} I albumin; meter setting 30,000 cpm full scale deflection; peak concentration 18,000 cpm above baseline; time constant 2 sec; cardiac output 8.2 L/min (cardiac index 4.2 L/min/M²). Curve on right: Fifteen μc^{131} I albumin; meter setting 100,000 cpm; peak 60,000 cpm above baseline; time constant 2 sec; cardiac output 8.7 L/min (cardiac index 4.4 L/min/M²).

RALPH J. GORTEN

DISCUSSION

This study is, to our knowledge, the first evaluation of the use of ¹²⁵I albumin and small uncollimated detectors for the determination of cardiac output. The physical characteristics of ¹²⁵iodine provide several advantages over other isotopes used previously for precordial counting. Energy emission in the form of a 35.4 kev gamma ray (2) permits efficient detection by small scintillation crystals such as the 2 mm thick wafer used in this study. This small, light detector has very low background counting rates.

On theoretical grounds, external counting of the 35.4 kev gamma emission might not have turned out to be feasible. Body tissues would be expected to provide an effective filter for ¹²⁵I activity as indicated by its broad-beam half-thickness of one inch in cheese (2). It seemed unlikely that enough radioactivity would survive transit through the cardiac and thoracic walls to permit the use of doses within reasonable limits. In practice, however, 20 μ c of ¹²⁵I for the first and 40 μ c for the second determination were sufficient to produce well defined precordial counting curves in patients varying considerably in body size and cardiac output.

Furthermore, the particles of energy which do survive transit through the thorax to reach the external detector probably travel in straight lines. It is unlikely that significant amounts of scattered gamma radiation from ¹²⁵I reach the detector. This can be substantiated by recalling three lines of evidence. First, without narrow angle collimation the ¹³¹I albumin-precordial counting method provided values for cardiac output significantly different from those obtained

Patient	¹²⁵ I Albumin Cardiac Output (L/min)	¹³¹ I Albumin Cardiac Output (L/min)		Patient	¹²⁵ [Albumin Cardiac Output (L/min)	¹³¹ I Albumin Cardiac Output (L/min)
G.H.	5.0	5.4		W.G.	5.4	5.3
	4.6	4.4			5.0	5.5
T.W.	7.7	8.5		T.W.	6.9	64
ΙA	8.8	0 0			6.1	7.1
1	7.2	7.7		Т.Т.	4.3	5.1
O.N.	8 0	6.6		H.E.	5.9	5.4
	8.0	58			9.0	8.0
	0.1	5.0			7.7	7.3
W.T.	7.0	5.5		W.S.	6.9	9.4
	6.0	4.7			77	7 8
F.H.	5.4	5 3		WI	6.1	10.3
	4.3	4.3		••••	77	7 6
WH	8.0	8.6		DD	1.0	2 7
	8.0	87		K.D .	4.0	3.7
	0 2	0.7			49	4.5
J.S.	6.5	5.2		H.C.	5.1	4.9
	6.4	4.9	11		5.0	4.7

TABLE

with the longer established and accepted dye-arterial sampling and Fick principle technics (12). Second, after narrow angle collimation was added to minimize the contribution of scattered radioactivity emanating from extracardiac blood vessels (13, 14), cardiac output results were similar to those obtained by catheterarterial sampling methods (14-24). Lastly, in the present series of comparisons, the ¹³¹I method with narrow angle collimation and ¹²⁵I with uncollimated detectors gave similar values. Therefore, it seems logical to assume that only emanations from ¹²⁵I in the heart which travel in straight lines reach the precordial detector. This precludes the need for shielding and narrow angle collimation.

Fortunately, also, doses of ¹²⁵I are well within the acceptable range. Total body radiation from 60 μ c of ¹²⁵iodine albumin (two determinations of cardiac output) was 29 millirads. Duplicate measurements with ¹³¹I albumin in each patient (30 μ c) resulted in about 54 mr. The absence of β radiation from ¹²⁵I is responsible for this difference. The longer shelf-life is an additional convenience.

SUMMARY

Precordial counting of ¹²⁵iodine albumin with small, light weight detectors for determination of cardiac output is reported for the first time. The system works well in human subjects with an unshielded and uncollimated wafer scintillation crystal. Radiation exposures are lower than with comparable doses of ¹³¹I albumin. In 16 patients (62 determinations), including some with heart disease, cardiac output values measured with ¹²⁵I albumin and with ¹³¹I albumin showed a high degree of correlation.

REFERENCES

1. MYERS, W. G. AND VANDERLEEDEN, H. C.: Radioiodine I¹²⁵. J. Nucl. Med. 1:124, 1960.

2. Myers, W. G. and Vanderleeden, J. C.: Radioiodine-125. J. Nucl. Med. 1:149, 1960.

3. HARPER, P. V., SIEMENS, W. D., LATHROP, K. A. AND ENDLICH, H.: Production and use of iodine-125 J. Nucl. Med. 4:277, 1963.

4. HARPER, P. V., LATHROP, K. A., ENDLICH, H. L., SIEMENS, W. AND HARRISON, R. W.: Clinical applications of iodine-125 J. Nucl. Med. 3:337, 1962.

5. WINTER, C. C. AND MYERS, W. G.: I-125, A new radioisotope for the labeled hippuran renogram J. Urol. 88:100, 1962.

6. WINTER, C. C. AND MYERS, W. G.: Three new test agents for the radioisotope renogram: DISA-I¹³¹; EDTA-Cr⁵¹; and Hippuran-I¹²⁵ J. Nucl. Med. 3:273, 1962.

7. WILLIAMS, J. A., GRABLE, E. AND FINE, J.: A semiautomatic instrument for measuring blood volume. J.A.M.A. 178:1097, 1961.

8. ENDLICH, H., HARPER, P., BECK, R., SIEMENS, W. AND LATHROP, K.: The use of 1¹²⁵ to increase isotope scanning resolution Am. J. Roentgenology, Rad. Ther. and Nucl. Med. 87:148, 1962.

9. HOBBS, J. T., AND FILIPOV, A. M.: A new instrument for obtaining indicator dilution curves using a radioactive tracer, I¹²⁵ Brit. Heart J. 26:75, 1964.

10. CORTEN, R. J. AND STAUFFER, J. C.: A study of the techniques and sources of error in the clinical application of the external counting method of estimating cardiac output Am. J. Med. Sci. 238:274, 1959.

11. CORTEN, R. J. AND HUGHES, H. M.: Extrapolation of precordial counting curves J. Nucl. Med. 4:485, 1963.

12. SHIPLEY, R. A., CLARK, R. E., LIEBOWITZ, D. AND KROHMER, J. S.: Analysis of the radiocardiogram in heart failure *Circulation Res.* 1:428, 1953.

13. VEALL, N., PEARSON, J. D., HANLEY, T. AND LOWE, A. E.: A method for the determination of cardiac output *Proc. Radioisotope Conf. 2nd Conf.* Oxford 1954, 1:183, 1954.

14. HUFF, R. L., FELLER, D. D., JUDD, O. J. AND BOGARDUS, G. M.: Cardiac output of men and dogs measured by in vivo analysis of iodinated (I¹³¹) human serum albumin *Circulation Res.* 3:564, 1955.

15. PRITCHARD, W. H., MACINTYRE, W. J. AND MOIR, T. W.: The determination of cardiac output by the dilution method without arterial sampling J. Lab. Clin. Med. 46:939, 1955.

16. ZIPF, R. E., WEBBER, J. M., GROVE, G. R. AND MCGUIRE, T. F.: Blood Volume and Cardiac Output Determinations Using Radioisotopes. WADC Technical Report 56-574, November, 1956.

17. MACK, R. E., WELLS, H. J., AND POLLACK, R.: An in vivo method for the determination of cardiac output. Radiology 68:245, 1957.

18. Albert, S. N., Spencer, W. A., Albert, C. A., Shibuya, J. and Henley, E. E.: U.S. Atomic Energy Commission Report AECU-3614, Part II. Index of cardiac clearance, 1958.

19. SHACKMAN, R.: Radio-active isotope measurements of cardiac output Clin. Sci. 17:317, 1958.

20. VAN DER FEER, Y., DOUMA, J. H. AND KLIP, W.: Cardiac output measurement by the injection method without arterial sampling Am. Heart J. 56:642, 1958.

21. PRITCHARD, W. H., MACINTYRE, W. J. AND MOIR, T. W.: The determination of cardiac output by the dilution method without arterial sampling. II. Validation of precordial recording *Circulation* 18:1147, 1958.

22. SELDON, W. A., HICKIE, J. B. AND GEORGE, E. P.: Measurement of cardiac output using a radioisotope and a scintillation counter *Brit. Heart J.* 21:401, 1959.

23. SCHREINER, B. F., JR., LOVEJOY, F. W., JR. AND YU, P. N.: Estimation of cardiac output from precordial dilution curves in patients with cardiopulmonary disease *Circulation Res.* 7:595, 1959.

24. GUNNELLS, J. C. AND GORTEN, R.: Effect of varying indicator injection sites on values for cardiac output J. Appl. Physiol. 16:261, 1961.